Consensus practice guidelines for bisphosphonate-associated osteonecrosis of the jaw.
Sambrook
Philip N
PN
Kolling Institute, Royal North Shore Hospital, University of Sydney, Sydney, Australia. sambrook@med.usyd.edu.au
D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D001847:Bone Diseases / Q000188:drug therapy; D002170:Canada; D004164:Diphosphonates / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007571:Jaw Diseases / Q000139:chemically induced*; D010001:Osteitis Deformans / Q000188:drug therapy; D010020:Osteonecrosis / Q000139:chemically induced*; D010024:Osteoporosis / Q000188:drug therapy; D018570:Risk Assessment
D050071:Bone Density Conservation Agents; D004164:Diphosphonates